AKTS insider buying – Aktis Oncology, Inc.
4 insider purchases since 2016 worth $79.3M by 4 different insiders. Last 12 months: 4 purchases, $79.3M. Most recent filing: 2026-01-14.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| NODELMAN OLEG Director | $40.0M 1× · 2,222,222 sh | 2026-01-12 2026-01-12 | – | 347,305 shares as of 2026-01-12 | Holds - never sold |
| GADICKE ANSBERT 10% Owner | $20.0M 1× · 1,112,777 sh | 2026-01-12 2026-01-12 | – | 7,570,168 shares as of 2026-01-14 | Holds - never sold |
| Kim Helen Susan Director | $15.0M 1× · 835,000 sh | 2026-01-12 2026-01-12 | – | 5,671,825 shares as of 2026-01-12 | Holds - never sold |
| Foley Todd Director | $4.2M 1× · 232,870 sh | 2026-01-12 2026-01-12 | – | 4,002,533 shares as of 2026-01-14 | Holds - never sold |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 4 | $79.3M | 4 | 5 | $3.2M |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2026-01-14 | GADICKE ANSBERT | 10% Owner | 1,112,777 | $18.00 | $20.0M | +12.2% | SEC |
| 2026-01-14 | Foley Todd | Director | 232,870 | $18.00 | $4.2M | +5.8% | SEC |
| 2026-01-12 | NODELMAN OLEG | Director | 2,222,222 | $18.00 | $40.0M | +104.5% | SEC |
| 2026-01-12 | Kim Helen Susan | Director | 835,000 | $18.00 | $15.0M | +17.3% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Czibere Akos | Officer | 12,500 | $20.69 | $258,592 | Sale | SEC |
| 2026-07-21 | Herrmann Ken | Director | 4,856 | $24.56 | $119,263 | Sale | SEC |
| 2026-07-20 | Herrmann Ken | Director | 3,065 | $25.21 | $77,269 | Sale | SEC |
| 2026-07-10 | Ron-Bigger Shulamit | Officer | 50,000 | $27.75 | $1.4M | Sale | SEC |
| 2026-07-10 | Czibere Akos | Officer | 50,000 | $27.77 | $1.4M | Sale | SEC |
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free